Oligodendroglioma: Difference between revisions

	Oligodendroglioma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Oligodendroglioma from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Staging
History & Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Oligodendroglioma On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Oligodendroglioma All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Oligodendroglioma
CDC on Oligodendroglioma
Oligodendroglioma in the news
Blogs on Oligodendroglioma
Directions to Hospitals Treating Oligodendroglioma
Risk calculators and risk factors for Oligodendroglioma

	Oligodendroglioma;
ICD-10	C71
ICD-9	191.9
ICD-O:	9450/3-9451/3
DiseasesDB	29450
MeSH	D009837

VisualWikitext

Revision as of 19:36, 17 January 2012

For patient information click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Historical Perspective

Pathophysiology

Epidemiology & Demographics

Risk Factors

Screening

Causes

Differentiating Oligodendroglioma

Complications & Prognosis

Diagnosis

Treatment

References

Template:Nervous tissue tumors Template:SIB de:Oligodendrogliom

Template:WikiDoc Sources

@@ Line 41: / Line 41: @@
 ==Treatment==
 [[Oligodendroglioma medical therapy|Medical therapy]] | [[Oligodendroglioma surgery|Surgical options]] | [[Oligodendroglioma primary prevention|Primary prevention]]  | [[Oligodendroglioma secondary prevention|Secondary prevention]] | [[Oligodendroglioma cost-effectiveness of therapy|Financial costs]] | [[Oligodendroglioma future or investigational therapies|Future therapies]]
-==Prognosis & treatment==
-Oligodendrogliomas are generally felt to be incurable using current treatments.  However compared to the more common [[astrocytomas]], they are slowly growing with prolonged survival.  In one series, [[median]] survival times for oligodendrogliomas were 11.6 years for grade II and 3.5 years for grade III.<ref> Ohgaki H, Kleihues P. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15977639&query_hl=10&itool=pubmed_docsum Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.] ''J Neuropathol Exp Neurol''. 2005 Jun;64(6):479-89. PMID: 15977639</ref>
-Long-term survival is reported in a minority of patients.<ref>Tatter SB. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12392640&query_hl=7&itool=pubmed_DocSum Recurrent malignant glioma in adults.] ''Curr Treat Options Oncol''. 2002 Dec;'''3'''(6):509-24. PMID: 12392640,</ref> With aggressive treatment and close monitoring, it is possible to outlive the typical life expectancies for both low grade and high grade oligodendrogliomas. In rare cases, patients have survived for up to fifteen years post-diagnosis. Westergaard’s
-study (1997) showed that patients younger than 20 years had a median survival of 17.5 years.<ref>Herbert H. Engelhard, M.D., Ph.D., Ana Stelea, M.D., and Arno Mundt, M.D.[http://www.virtualtrials.com/pdf/oligo.pdf] p.449</ref> Another study shows a 34% survival rate after 20 years. <ref> {{cite journal |author=Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB, Friedman WA |title=Oligodendroglioma: does deferring treatment compromise outcome? |journal=Am. J. Clin. Oncol. |volume=26 |issue=3 |pages=e60-6 |year=2003 |pmid=12796617 |doi=10.1097/01.COC.0000072507.25834.D6}}</ref>
 ==References==